Maze Therapeutics (MAZE) Invested Capital (2024 - 2026)

Maze Therapeutics has disclosed Invested Capital across 3 years of filings, most recently posting $380.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $380.5 million, up 30.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $380.5 million (up 30.29% YoY), and the FY2025 annual result was $355.0 million, up 214.07% from the prior year.
• Invested Capital came in at $380.5 million for Q1 2026 at Maze Therapeutics, up from $355.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $380.5 million in Q1 2026 to a low of -$403.7 million in Q1 2024.
• The 3-year median for Invested Capital is $262.2 million (2025), against an average of $45.3 million.
• Across the five-year window, Invested Capital soared 233.35% in 2025 and soared 30.29% in 2026, its largest moves.
• Maze Therapeutics' Invested Capital stood at -$311.2 million in 2024, then jumped by 214.07% to $355.0 million in 2025, then rose by 7.2% to $380.5 million in 2026.
• The last three Invested Capital figures came in at $380.5 million (Q1 2026), $355.0 million (Q4 2025), and $379.4 million (Q3 2025), per Business Quant data.